Literature DB >> 9710526

Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat.

D Kirik1, C Rosenblad, A Björklund.   

Abstract

Partial lesions of the nigrostriatal dopamine system have been investigated with respect to their ability to induce consistent long-lasting deficits in movement initiation and skilled forelimb use. In eight different lesion groups 6-hydroxydopamine (6-OHDA) was injected at one, two, three, or four sites into the lateral sector of the right striatum, in a total dose of 20-30 microgram. Impairments in movement initiation in a forelimb stepping test, and in skilled paw use in a paw-reaching test, was seen only in animals where the severity of the lesion exceeded a critical threshold, which was different for the different tests used: single (1 x 20 microgram) or two-site (2 x 10 microgram) injections into the striatum had only small affects on forelimb stepping, no effect on skilled paw use. More pronounced deficits were obtained in animals where the same total dose of 6-OHDA was distributed over three or four sites along the rostro-caudal extent of the lateral striatum or where the injections were made close to the junction of the globus pallidus. The results show that a 60-70% reduction in tyrosine hydroxylase (TH)-positive fiber density in the lateral striatum, accompanied by a 50-60% reduction in TH-positive cells in substantia nigra (SN), is sufficient for the induction of significant impairment in initiation of stepping. Impaired skilled paw-use, on the other hand, was obtained only with a four-site (4 x 7 microgram) lesion, which induced 80-95% reduction in TH fiber density throughout the rostrocaudal extent of the lateral striatum and a 75% loss of TH-positive neurons in SN. Drug-induced rotation, by contrast, was observed also in animals with more restricted presymptomatic lesions. The results indicate that the four-site intrastriatal 6-OHDA lesion may be a relevant model of the neuropathology seen in parkinsonian patients in a manifest symptomatic stage of the disease and may be particularly useful experimentally since it leaves a significant portion of the nigrostriatal projection intact which can serve as a substrate for regeneration and functional recovery in response to growth promoting and neuroprotective agents. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9710526     DOI: 10.1006/exnr.1998.6848

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  157 in total

1.  Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer.

Authors:  Deniz Kirik; Biljana Georgievska; Corinna Burger; Christian Winkler; Nicholas Muzyczka; Ronald J Mandel; Anders Bjorklund
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-26       Impact factor: 11.205

2.  The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease.

Authors:  E Ilijic; J N Guzman; D J Surmeier
Journal:  Neurobiol Dis       Date:  2011-04-16       Impact factor: 5.996

3.  Neurturin protects against 6-hydroxydopamine-induced reductions in evoked dopamine overflow in rat striatum.

Authors:  Wayne A Cass; Laura E Peters
Journal:  Neurochem Int       Date:  2010-07-06       Impact factor: 3.921

4.  Oxidative stress and dopamine depletion in an intrastriatal 6-hydroxydopamine model of Parkinson's disease.

Authors:  M P Smith; W A Cass
Journal:  Neuroscience       Date:  2006-11-15       Impact factor: 3.590

5.  Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease.

Authors:  Melissa K McCoy; Terina N Martinez; Kelly A Ruhn; David E Szymkowski; Christine G Smith; Barry R Botterman; Keith E Tansey; Malú G Tansey
Journal:  J Neurosci       Date:  2006-09-13       Impact factor: 6.167

6.  Striatal pleiotrophin overexpression provides functional and morphological neuroprotection in the 6-hydroxydopamine model.

Authors:  Sara E Gombash; Jack W Lipton; Timothy J Collier; Lalitha Madhavan; Kathy Steece-Collier; Allyson Cole-Strauss; Brian T Terpstra; Anne L Spieles-Engemann; Brian F Daley; Susan L Wohlgenant; Valerie B Thompson; Fredric P Manfredsson; Ronald J Mandel; Caryl E Sortwell
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

7.  Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy.

Authors:  Nadia Stefanova; Markus Reindl; Manuela Neumann; Christian Haass; Werner Poewe; Philipp J Kahle; Gregor K Wenning
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

8.  Acute perinatal asphyxia impairs non-spatial memory and alters motor coordination in adult male rats.

Authors:  Nicola Simola; Diego Bustamante; Annalisa Pinna; Silvia Pontis; Paola Morales; Micaela Morelli; Mario Herrera-Marschitz
Journal:  Exp Brain Res       Date:  2007-11-08       Impact factor: 1.972

9.  Nociceptive behavioral responses to chemical, thermal and mechanical stimulation after unilateral, intrastriatal administration of 6-hydroxydopamine.

Authors:  Eric H Chudler; Ying Lu
Journal:  Brain Res       Date:  2008-04-08       Impact factor: 3.252

10.  Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease.

Authors:  J A Morales-García; C Susín; S Alonso-Gil; D I Pérez; V Palomo; C Pérez; S Conde; A Santos; C Gil; A Martínez; A Pérez-Castillo
Journal:  ACS Chem Neurosci       Date:  2012-12-05       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.